Ulster University Logo

Ulster Institutional Repository

Browse by Ulster Authors and Editors

Biomedical Sciences Research Institute Computer Science Research Institute Environmental Sciences Research Institute Nanotechnology & Advanced Materials Research Institute
Up a level
Export as [feed] RSS 2.0 [feed] RSS 1.0 [feed] Atom
Group by: Date | Item Type | No Grouping
Jump to: 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006
Number of items: 28.

2014

McClean, Paula L. and Hölscher, Christian (2014) Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease. Neuropharmacology., 86 . pp. 241-258. [Journal article]

2013

Graham, Stewart F., Holscher, Christian, McClean, Paula, Elliott, Christopher T. and Green, Brian D. (2013) 1H NMR metabolomics investigation of an Alzheimer’s disease (AD) mouse model pinpoints important biochemical disturbances in brain and plasma. Metabolomics, 9 (5). p. 974. [Journal article]

Long-Smith, Caitriona M, Manning, Sean, McClean, PL, Coakley, Meghan F, O'Halloran, Domhnall J, Holscher, Christian and O'Neill, Cora (2013) The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-β plaque and glial pathology in a mouse model of Alzheimer's disease. Neuromolecular medicine, 15 (1). pp. 102-14. [Journal article]

McClean, Paula L. and Hölscher, Christian (2013) Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease. Neuropharmacology, TBC . [Journal article]

Parthsarathy, Vadivel, McClean, Paula, Hölscher, Christian, Taylor, Mark, Tinker, Claire, Jones, Glynn, Kolosov, Oleg, Salvati, Elisa, Gregori, Maria, Masserini, Massimo and Allsop, David (2013) A novel retro-inverso peptide inhibitor reduces amyloid deposition, oxidation and inflammation and stimulates neurogenesis in the APPswe/PS1ΔE9 mouse model of Alzheimer's disease. PloS one, 8 (1). e54769. [Journal article]

2012

Bomfim, Theresa R, Forny-Germano, Leticia, Sathler, Luciana B, Brito-Moreira, Jordano, Houzel, Jean-Christophe, Decker, Helena, Silverman, Michael A, Kazi, Hala, Melo, Helen M, McClean, Paula, Holscher, Christian, Arnold, Steven E, Talbot, Konrad, Klein, William L, Munoz, Douglas P, Ferreira, Sergio T and De Felice, Fernanda G (2012) An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers. The Journal of clinical investigation, 122 (4). pp. 1339-53. [Journal article]

2011

McClean, Paula, Parthsarathy, Vadivel, Faivre, Emilie and Holscher, Christian (2011) The diabetes drug Liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. The Journal of Neuroscience, 31 (17). pp. 6587-6594. [Journal article]

2010

Gengler, Simon, McClean, Paula, McCurtin, Ruth, Gault, Victor and Holscher, Christian (2010) Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice. Neurobiol Aging, 000 . 000-000. [Journal article]

McClean, Paula, Gault, Victor A, Harriott, Patrick and Holscher, Christian (2010) Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: A link between diabetes and Alzheimer's disease. EUROPEAN JOURNAL OF PHARMACOLOGY, 630 (1-3). pp. 158-162. [Journal article]

McClean, Paula, Parthsarathy, V., Faivre, E. and Holscher, Christian (2010) The novel GLP-1 analogue liraglutide has neuroprotective properties in a mouse model of Alzheimer's disease. REGULATORY PEPTIDES, 164 (1, Sp. Iss. SI). p. 40. [Journal article]

2009

Holscher, Christian, Fung, K., McCurtin, R., Gault, Victor and McClean, Paula (2009) Novel GLP-1 analogues cross the blood brain barrier and enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease. DIABETOLOGIA, 52 (Suppl. 1). p. 790. [Journal article]

Irwin, Nigel, McClean, Paula, Hunter, Kerry and Flatt, Peter (2009) Metabolic effects of sustained activation of the GLP-1 receptor alone and in combination with background GIP receptor antagonism in high fat-fed mice. DIABETES OBESITY AND METABOLISM, 11 (6). pp. 603-610. [Journal article]

Irwin, Nigel, McClean, Paula, Patterson, Steven, Hunter, Kerry and Flatt, Peter (2009) Active immunisation against gastric inhibitory polypeptide (GIP) improves blood glucose control in an animal model of obesity-diabetes. BIOLOGICAL CHEMISTRY, 390 (1). pp. 75-80. [Journal article]

McClean, Paula, Gault, Victor, Harriott, Patrick and Holscher, Christian (2009) Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: A link between diabetes and Alzheimer's disease. European journal of pharmacology, epub . [Journal article]

O'Harte, FPM, McClean, PL and Irwin, N (2009) Structure function studies with glucagon related peptides reveal glucagon receptor antagonist activities in vitro and in vivo. In: 45th Annual Meeting of the European-Association-for-the-Study-of-Diabetes, Vienna. UNSPECIFIED. 1 pp. [Conference contribution]

2008

McClean, Paula, Gault, Victor, Irwin, Nigel, McCluskey, Janie and Flatt, Peter (2008) Daily administration of the GIP-R antagonist (Pro(3))GIP in streptozotocin-induced diabetes suggests that insulin-dependent mechanisms are critical to anti-obesity-diabetes actions of (Pro(3))GIP. DIABETES OBESITY AND METABOLISM, 10 (4). pp. 336-342. [Journal article]

McClean, Paula, Irwin, Nigel, Hunter, Kerry, Gault, Victor and Flatt, Peter (2008) (Pro(3)) GIP[mPEG]: novel, long-acting, mPEGylated antagonist of gastric inhibitory polypeptide for obesity-diabetes (diabesity) therapy. BRITISH JOURNAL OF PHARMACOLOGY, 155 (5). pp. 690-701. [Journal article]

2007

Gault, Victor, McClean, Paula, Cassidy, R. S., Irwin, Nigel and Flatt, Peter (2007) Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets. DIABETOLOGIA, 50 (8). pp. 1752-1762. [Journal article]

Gault, Victor, McClean, Paula, Irwin, Nigel, McCluskey, Janie and Flatt, Peter (2007) Effects of GIP-receptor antagonism in a streptozotocin-induced model of insulin deficiency. DIABETIC MEDICINE, 24 (Suppl. 1). p. 40. [Journal article]

Gault, Victor, McClean, Paula, Irwin, Nigel, Power, Gavin J., McCluskey, Janie and Flatt, Peter (2007) Effects of subchronic treatment with the long-acting glucose-dependent insulinotropic polypeptide receptor agonist, N-AcGIP, on glucose homeostasis in Streptozotocin-induced diabetes. PANCREAS, 35 (1). pp. 73-79. [Journal article]

Irwin, Nigel, McClean, Paula, Cassidy, Roslyn S, O'Harte, Finbarr, Green, Brian D, Gault, Victor, Harriott, Patrick and Flatt, Peter (2007) Comparison of the anti-diabetic effects of GIP- and GLP-1-receptor activation in obese diabetic (ob/ob) mice: studies with DPP IV resistant N-AcGIP and exendin(1-39)amide. DIABETES-METABOLISM RESEARCH AND REVIEWS, 23 (7). pp. 572-579. [Journal article]

Irwin, Nigel, McClean, Paula and Flatt, Peter (2007) Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice. JOURNAL OF PEPTIDE SCIENCE, 13 (6). pp. 400-405. [Journal article]

Irwin, Nigel, McClean, Paula, Harriott, Patrick and Flatt, Peter (2007) Beneficial effects of sub-chronic activation of glucagon-like peptide-1 (GLP-1) receptors on deterioration of glucose homeostasis and insulin secretion in aging mice. EXPERIMENTAL GERONTOLOGY, 42 (4). pp. 296-300. [Journal article]

Irwin, Nigel, McClean, Paula, O'Harte, Finbarr, Gault, Victor, Harriott, P and Flatt, Peter (2007) Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro(3))GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice. DIABETOLOGIA, 50 (7). pp. 1532-1540. [Journal article]

McClean, Paula, Gault, Victor, Irwin, Nigel, Power, G. J., McCluskey, Janie and Flatt, Peter (2007) Effects of daily administration of the glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, N-Acetyl-GIP, in streptozotocin-incluced diabetic mice. DIABETIC MEDICINE, 24 (Suppl. 1). pp. 40-41. [Journal article]

McClean, Paula, Irwin, Nigel, Cassidy, Roslyn S., Holst, Jens J., Gault, Victor and Flatt, Peter (2007) GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 293 (6). E1746-E1755. [Journal article]

O'Harte, Finbarr, Irwin, Nigel, Gault, Victor, McClean, Paula, Cassidy, RS, Harriott, P and Flatt, Peter (2007) Antidiabetic effects of sub-chronic administration of stable incretin mimetics N-AcGIP and exendin-4 (1-39) amide in obese-diabetic mice. DIABETIC MEDICINE, 24 (Suppl. 1). p. 22. [Journal article]

2006

Flatt, Peter, Irwin, Nigel, McClean, Paula, Green, BD, Gault, Victor, Bailey, CJ and O'Harte, Finbarr (2006) Early administration of the GIP receptor antagonist (Pro(3))GIP counters development of hyperglycaemia, glucose intolerance and insulin resistance in genetic obesity. DIABETOLOGIA, 49 (Suppl. 1). 0171. [Journal article]

This list was generated on Tue Nov 25 08:43:48 2014 GMT.